We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI,” said, James ...
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its ...
Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
(RTTNews) - Revelation Biosciences, Inc. (REVB), a clinical-stage life sciences company, announced on Monday that the FDA has accepted its Investigational New Drug (IND) application for Gemini, ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results